What is known and objective: SB5 is a biosimilar to the reference adalimumab (ADL) currently in development. The primary study objective was to demonstrate pharmacokinetic (PK) equivalence of SB5 to European Union-sourced adalimumab (EU-ADL), and United States-sourced adalimumab (US-ADL) in healthy subjects. Safety, tolerability and immunogenicity were also assessed as secondary objectives.
| WHAT IS KNOWN AND OBJECTIVE
Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease of the joints that is associated with significant morbidity and is a physical and economic burden to both the patient and society. [1] [2] [3] Although effective disease-modifying antirheumatic drugs such as methotrexate (MTX) are available, not all patients respond to them. 4 The introduction of tumour necrosis factor alpha (TNF-α) antagonists, such as adalimumab, has markedly improved RA treatment outcomes and greatly inhibited the progression of joint damage. [4] [5] [6] [7] A biosimilar is a biological agent that contains a highly similar active ingredient of an approved biological drug (reference product). 8 Unlike generic drugs, biosimilars differ chemically from their reference products owing to their complex manufacturing process. [8] [9] [10] In addition, the approval process for biosimilars differs significantly from that of generic drugs, in that biosimilar manufacturers must establish pharmaceutical quality, preclinical characterization, conformity of clinical trials to the pertinent guideline for desired product, and prevention of immune responses to the biosimilar. 10, 11 SB5 is a proposed biosimilar to Humira ® (adalimumab, AbbVie Inc, North Chicago, IL, USA) that has an identical amino acid sequence and similar physicochemical and in vitro functional properties.
12,13
Adalimumab binds specifically to TNF-α and neutralizes its biological function by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leucocyte migration.
13
In accordance with the European Medicines Agency biosimilar guidelines, 14, 15 the development of SB5 has involved biosimilarity studies starting with the comparison of structural characteristics, physicochemical properties and biological activities between SB5 and adalimumab, followed by the demonstration of similar in vivo behaviour for the two agents. A pivotal phase III study has been completed demonstrating the equivalence of SB5 to European Union-sourced adalimumab (EU-ADL) in terms of the ACR20 response rate at week 24 in patients with moderate to severe RA despite MTX therapy.
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This phase I study (NCT02144714) was designed to demonstrate pharmacokinetic (PK) similarity between SB5 and EU-ADL, between SB5 and United States-sourced adalimumab (US-ADL), and between EU-ADL and US-ADL after a single administration of adalimumab in healthy subjects.
| METHODS

| Study population and design
Healthy subjects, 18-55 years of age, were eligible for this phase I, randomized, single-blind, three-arm, parallel-group, single-dose, single-centre study. Written informed consent was obtained from all study participants. The study was conducted in accordance with the Declaration of Helsinki and is consistent with the International Conference on Harmonization Good Clinical Practice guidelines.
To be included in the study, subjects were required to be healthy females of non-childbearing potential or males with a body weight between 65 and 90 kg and a body mass index between 20 and The primary objective of the study was to demonstrate PK equivalence of SB5 to EU-ADL and US-ADL in healthy subjects in regard to AUC inf , AUC last and C max. Secondary objectives included safety, tolerability and immunogenicity assessments. linear regression analysis using the last three (or more) nonzero concentrations; however, if the regression slope could not be estimated due to time to reach C max (T max ) being one of the last three points in the respective profiles, subjects were excluded from the PK analysis (summary statistics and ANOVA for PK parameters).
| Pharmacokinetic evaluations
| Safety evaluations
Safety assessments included measurements of adverse events (AEs), 
| Immunogenicity evaluations
| Statistical analysis
A sample size of 56 completing subjects from each group of the clinical study was estimated to provide 90% power to detect a 20% difference in PK between the test product and reference product, based on an assumption of 5% difference in true geometric means between test and reference products and 32% intersubject coefficient of variation percentage (CV%). As a 10% dropout rate was anticipated, 189 subjects (n=63 in each arm) were required to be randomized in the study.
Pharmacokinetic parameters were calculated based on actual sampling times relative to dosing and non-compartmental analysis methods 
| RESULTS
| Subject disposition
This study was conducted from 2 May 2014 to 2 September 2014.
Of 351 subjects screened for study enrolment, 189 were randomized into three treatment groups to receive assigned study product (SB5, n=63; EU-ADL, n=63; US-ADL, n=63) ( Figure S1 ). All subjects completed the study, and no subjects were prematurely discontinued.
Minor protocol deviations that did not affect the study outcomes, such as PK blood sampling-related study procedure, study procedure and immunogenicity-related study procedure, were reported by 34.9% of patients (SB5, 38.1%; EU-ADL, 36.5%; US-ADL,
30.2%).
Due to a major protocol deviation, including receiving concomitant medications for treatment of AE (psychotic disorder with aggressive behaviour/alcohol intoxication and fluid infusions during and/or after operation of appendicitis), which would influence the PK, two (1.1%) subjects from the randomized set were excluded from the PK population of the study. Of the remaining subjects in the PK population, 16 subjects were excluded from the PK analysis (SB5, n=9; EU-ADL, n=2;
US-ADL, n=5) as the regression slope could not be reliably estimated for these subjects due to the T max being one of the last three points in the respective profiles. Overall, PK analysis was performed in 53 subjects in the SB5 treatment group, 61 subjects in the EU-ADL treatment group and 57 subjects in the US-ADL treatment group.
Baseline characteristics and demographics were comparable between treatment groups (Table 1) . Mean (SD) age of subjects was 39.5 (10.5) years. The majority of subjects were male (92.1%) and Caucasian 
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| Pharmacokinetic evaluations
The mean serum concentration-time profiles between SB5 and each reference product and between the two reference products were superimposable ( Figure 1 ).
The mean PK parameters were comparable across the three treatment groups as shown in Table 2 . For the primary PK parameters AUC inf , AUC last and C max , the 90% CIs were well within 0.8-1.25, demonstrating PK equivalence between SB5 and EU-ADL and US-ADL, and between EU-ADL and US-ADL ( A separate analysis was conducted to investigate PK parameters when including 16 subjects who were excluded from the PK analysis as previously described. This additional analysis did not alter the conclusions of the PK analysis because all PK parameters were equivalent across all treatment groups. The 90% CI for all the test-to-reference ratios of AUC inf , AUC last and C max were within the predefined equivalence margin (Table S1 ).
| Safety evaluations
All 189 subjects randomized in the study were evaluated for safety.
No discontinuations due to TEAEs or deaths were reported during the study. SAEs were reported in two subjects (SB5, n=1; US-ADL, n=1) but were not considered study drug related. There was only one subject with a total injection-site reaction score
F I G U R E 1 Mean serum concentration-time profiles of SB5, EU-ADL and US-ADL. (A) Linear scale (B) Semilogarithmic scale. EU-ADL, European Union-sourced adalimumab; US-ADL, United Statessourced adalimumab
SB5 (N=62) EU-ADL (N=63) US-ADL (N=62)
Subjects in PK analysis (n) 53 61 57 Data are presented in (mean±SD) except T max , which is presented in median (min-max); 16 subjects from the PK population were excluded from PK analysis. AUC inf , area under the concentration-time curve from time zero to infinity; AUC last , area under the concentration-time curve from time zero to the last quantifiable concentration; C max , maximum concentration; CL/F, apparent clearance; EU-ADL, European Union-sourced adalimumab; PK, pharmacokinetic; t 1/2 , terminal half-life; T max , time to reach C max ; US-ADL, United States-sourced adalimumab; Vz/F, apparent volume of distribution. 
| Immunogenicity evaluations
The incidence of subjects with post-dose ADA to adalimumab was considered comparable across all three treatment groups and occurred in 98.4% of subjects in the SB5 treatment group, 95.2% of subjects in the EU-ADL treatment group and all subjects in the US-ADL treatment group (Table 5) . No statistically significant difference in post-dose ADA incidence was observed across treatment groups:
between SB5 and EU-ADL (P=.6189), between SB5 and US-ADL (P=1.0000) and between EU-ADL and US-ADL (P=.2440).
In a subgroup analysis, the impact of ADA on PK parameters was evaluated (Table S2) . Across all treatment groups, higher ADA titre was associated with lower PK parameters such as AUC inf and AUC last , but was associated with higher drug clearance. PK parameters, such as AUC inf , AUC last , C max , CL/F and t 1/2 , were comparable between SB5
and each reference product within each ADA-negative and ADApositive subgroups and by ADA titre level.
| DISCUSSION
The purpose of this study was to investigate and compare the PK profiles, safety, tolerability and immunogenicity of SB5 with EU-ADL, of SB5 with US-ADL and of EU-ADL with US-ADL in healthy subjects.
For measuring PK characteristics, healthy subjects are a more sensitive population than patient population as they are more homogenous and do not have various disease-related factors that can influence the PKs of study drugs. 15 Following recommendations to use the highest dose in comparative PK studies, 17 a single dose of 40 mg was used.
As crossover designs with ADL are not feasible due to its long t 1/2 , a parallel study design was used.
18
Equivalence of the PK between the test and reference product was to be concluded if the 90% CIs for the geometric LS means ratios of the primary study variables, AUC inf , AUC last and C max , were within the accepted range of 0.8-1.25. Following administration of either SB5, EU-ADL or US-ADL, equivalence criteria were met for all primary PK
variables. This primary analysis excluded 16 subjects who did not satisfy the criteria to be included in the PK analysis. For accurate estimation of λz from linear regression, it is recommended to obtain at least three to four samples during the terminal log-linear phase. 17 These 16 subjects had insufficient drug concentrations needed for estimating λz possibly due to a higher ADA titre compared with the entire study population. All these subjects had positive ADA results post-dose Day 15, and the median ADA titres were 12, 32 and 64 compared to 8, 8 and 8 in the entire study population for SB5, EU-ADL and US-ADL, respectively. The relatively higher titres of ADA could theoretically increase ADL drug clearance.
To ensure the robustness of the results, the authors conducted a sensitivity analysis including these 16 subjects, and the results were consistent with the primary analysis and the equivalence criteria were met for all pairwise comparisons and confirm that SB5, EU-ADL and US-ADL are all bioequivalent.
There were no deaths or discontinuation due to TEAEs during the study. Two SAEs occurred in two subjects; one subject from the SB5 treatment group experienced a psychotic disorder, and one subject from the US-ADL treatment group experienced an appendicitis; both events were assessed by the investigator not to be related to the study drug. The proportion of subjects in the SB5 treatment group who experienced TEAEs was comparable to subjects in the reference treatment groups (EU-ADL or US-ADL). 16 subjects from the PK population were excluded from PK analysis. AUC inf , area under the concentration-time curve from time zero to infinity; AUC last , area under the concentration-time curve from time zero to the last quantifiable concentration; C max , maximum concentration; EU-ADL, European Union-sourced adalimumab; LS, least squares; PK, pharmacokinetic; US-ADL, United States-sourced adalimumab.
T A B L E 3 Statistical comparison of primary PK parameters between test and reference products (PK population)
ECG data did not show any significant changes over time considered to be related to the products.
The incidence of ADA was comparable across the three treatment groups and the respective incidence for SB5, EU-ADL and US-ADL was 98.4%, 95.2% and 100%. These ADA results are higher than that observed in other studies with ADL and may be due to the higher sensitivity (5.37 ng/mL) of the ELISA assay used in this study. 13 The incidence of post-dose NAb to ADL among the subjects with a positive ADA result was comparable across the three treatment groups; 49 of 62 (79.0%) subjects in the SB5 treatment group, 48 of 60 (80.0%) subjects in the EU-ADL treatment group and 52 of 63 (82.5%) subjects in the US-ADL treatment group had a positive result for NAb.
A subgroup analysis by ADA titre (low, medium, high) showed that the PK parameters (AUC inf and AUC last ) were lower in the high ADA titre group, possibly due to the higher rate of clearance compared to the low ADA titre group. These results are consistent with previous study results that demonstrate ADAs are associated with lower adalimumab serum concentrations and diminished clinical response, such as treatment discontinuations, higher disease activity and lower rates of remission. 12, 19 Additionally, ADA can have an impact on the PK of therapeutic proteins by enhancing clearance; however, the mechanism of action of this impact has not been extensively investigated. 20 Within each subgroup of this study, by ADA titre, the PK parameters were comparable between SB5 and EU-ADL, SB5 and US-ADL, and EU-ADL and US-ADL.
| WHAT IS NEW AND CONCLUSIONS
Pharmacokinetic similarity between SB5 and EU-ADL, between SB5
and US-ADL and between EU-ADL and US-ADL was demonstrated in healthy subjects. All three ADL products were generally well tolerated T A B L E 4 Summary of TEAEs occurring in ≥5% of subjects Percentages for ADA result were based on the number of subjects with available ADA assessment results at each time point; Percentages for NAb result were based on the number of subjects with positive ADA at each relevant time point; Post-dose overall defined as subjects who had positive ADA or NAb on either Day 15 or Day 71. ADA, antidrug antibody; EU-ADL, European Union-sourced adalimumab; n, number of subjects with applicable result; n', number of subjects with available assessment results at each time point; NAb, neutralizing antibody; US-ADL, United States-sourced adalimumab.
T A B L E 5 Incidence of ADAs and NAbs to adalimumab
